Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Receivables (2016 - 2025)

Fortress Biotech (FBIO) has 11 years of Receivables data on record, last reported at $18.0 million in Q3 2025.

  • For Q3 2025, Receivables rose 68.52% year-over-year to $18.0 million; the TTM value through Sep 2025 reached $18.0 million, up 68.52%, while the annual FY2024 figure was $10.2 million, 33.23% down from the prior year.
  • Receivables reached $18.0 million in Q3 2025 per FBIO's latest filing, up from $15.6 million in the prior quarter.
  • Across five years, Receivables topped out at $31.7 million in Q3 2021 and bottomed at $8.0 million in Q3 2023.
  • Average Receivables over 5 years is $20.2 million, with a median of $18.9 million recorded in 2021.
  • Peak YoY movement for Receivables: skyrocketed 684.46% in 2021, then tumbled 72.0% in 2023.
  • A 5-year view of Receivables shows it stood at $23.5 million in 2021, then increased by 28.05% to $30.1 million in 2022, then tumbled by 49.11% to $15.3 million in 2023, then tumbled by 33.23% to $10.2 million in 2024, then surged by 75.77% to $18.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $18.0 million in Q3 2025, $15.6 million in Q2 2025, and $18.0 million in Q1 2025.